Skip to main content
Terug
Watch Compare

Damora Therapeutics, Inc.

Datakwaliteit: 83%
DMRA
Nasdaq Manufacturing Chemicals
€ 25,82
▼ € 0,87 (-3,26%)
Marktkapitalisatie: 1,56 B
Prijs
€ 25,82
Marktkapitalisatie
1,56 B
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -6,73 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-2213,49%
Onder sectorgemiddelde (-53,53%)
ROIC-1737,56%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio3,73
Interest Coverage-180,70

Waardering

PE (TTM)
-7,42
Onder sectorgemiddelde (-1,48)
P/B Ratio194,46
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)
Metriek Aandeel Sector Mediaan
P/E -7,4 -1,5
P/B 194,5 1,6
ROE % -2213,5 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

5 analisten
Buy
Huidig
€ 25,82
+78.9%
Koersdoel
€ 46,20
€ 40,00
€ 45,00
€ 55,00
Vooruitzicht
Forward WPA -€ 1,74
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 1,74
-€ 2,03 – -€ 1,36
 0,0 4
FY2026 -€ 1,32
-€ 1,95 – -€ 0,95
 0,0 4

Winstverassingen

Laatste 2 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,11 N/A —
Q32025 N/A -€ 2,36 —

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -209,84 M
ROE -2213,49% ROA -1718,09%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -6,73 M
ROIC -1737,56% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,73
Interest Coverage -180,70 Asset Turnover N/A
Working Capital 7,16 M Tangible Book Value 8,01 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -7,42 Forward P/E N/A
P/B Ratio 194,46 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -0,43%
Market Cap 1,56 B Enterprise Value 1,55 B
Per Share
EPS (Diluted TTM) 3,98 Revenue / Share N/A
FCF / Share -0,11 OCF / Share -0,11
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 3,21%
SBC-Adj. FCF -7,92 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -209,84 M -21,44 M -38,35 M -61,62 M -51,75 M
EPS (Diluted) 3,98 -18,53 -1,44 -2,43 —
Gross Profit — — — — —
Operating Income -210,87 M -22,26 M -39,91 M -61,21 M -52,23 M
EBITDA — — — — —
R&D Expenses 26,88 M 6,40 M 23,77 M 48,21 M 38,49 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 1,17 M 844.000,0 1,69 M 722.000,0 156.000,0
Income Tax 50.000,0 41.000,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 260,53 M 17,13 M 38,23 M 73,19 M 122,22 M
Total Liabilities 20,15 M 1,30 M 5,90 M 11,44 M 4,99 M
Shareholders' Equity 240,38 M 15,83 M 32,33 M 61,75 M 117,22 M
Total Debt — — — — —
Cash & Equivalents 257,62 M 14,18 M 21,47 M 32,79 M 62,56 M
Current Assets 260,42 M 16,84 M 36,77 M 63,91 M 110,10 M
Current Liabilities 20,07 M 1,20 M 5,83 M 11,11 M 4,54 M